Low sCD163/TWEAK Ratio at First Day After Acute Myocardial Infarction Associated with Adverse Cardiac Remodeling in Non-Elderly Patients

Aim    In this study, we aimed to investigate the role of sCD163 / tumor necrosis factor-like weak apoptosis-inducing (TWEAK) ratio in cardiac remodeling in non-elderly patients diagnosed with first acute myocardial infarction (MI).
Material and Methods    Forty-four patients (age ranges: 40–64 years) diagnosed with first-time acute ST-elevation MI in the emergency department were evaluated with cardiac magnetic resonance (CMR) imaging. Adverse remodeling (AR) was defined the increases of left ventricular end-diastolic volume by ≥12 % by CMR at 6‑month post-MI TWEAK and sCD163 were measured at the first day (baseline), 2 weeks and 6 weeks post-MI.
Results    The average age of patients included in the study was 53.6±5.1 years. AR was detected in 18 patients at the 6 months post-MI. At the first day post-MI, median sCD163 concentration (116 069 vs 86 394 pg / mL, p=0.040) and median TWEAK concentration (759.4 vs 220.1 pg / mL, p<0.001) were higher in AR group compared to group without AR (the non-AR group), median sCD163 / TWEAK ratio (101.4 vs. 406.8; p<0.001) was lower. At the first day post-MI, concentrations of TWEAK and sCD163 showed a positive correlation in AR group and group without AR s. At 2 weeks post-MI, positive correlation continued in the non-AR group, but no significant correlation was found in the AR group. At the first day post-MI, sCD163 / TWEAK ratio was higher diagnostic performance compared to TWEAK and sCD163.
Conclusion    In the early phase post-MI, the relationship between sCD163 – TWEAK may have an important role in AR pathogenesis. A lower sCD163 / TWEAK ratio on the first day after MI was associated with an increase in left ventricular end-diastolic volume after 6 months of follow-up.

1. Ryabov V.V., Gombozhapova A.E., Rogovskaya Yu.V., Rebenkova M.S., Alekseeva Yu.V., Kzhyshkowska Yu.G. Inflammation as a universal pathogenetic link between injury, repair and regeneration, in acute coronary syndrome. From experiment to clinic. Kardiologiia. 2019;59(S8):15–23. DOI: 10.18087/cardio.2668

2. Swirski FK, Nahrendorf M. Cardioimmunology: the immune system in cardiac homeostasis and disease. Nature Reviews Immunology. 2018;18(12):733–44. DOI: 10.1038/s41577-018-0065-8

3. Kologrivova I, Shtatolkina M, Suslova T, Ryabov V. Cells of the Immune System in Cardiac Remodeling: Main Players in Resolution of Inflammation and Repair After Myocardial Infarction. Frontiers in Immunology. 2021;12:664457. DOI: 10.3389/fimmu.2021.664457

4. Berezin AE, Berezin AA. Adverse Cardiac Remodelling after Acute Myocardial Infarction: Old and New Biomarkers. Disease Markers. 2020;2020:1215802. DOI: 10.1155/2020/1215802

5. Kapustina A.Yu., Minushkina L.O., Alekhin M.N., Selezneva N.D., Safaryan V.I., Brazhnik V.A. et al. Left ventricular global function index as a predictor of adverse cardiovascular events in patients with acute coronary syndrome. Kardiologiia. 2021;61(8):23–31. DOI: 10.18087/cardio.2021.8.n1508

6. Méndez-Barbero N, Gutierrez-Muñoz C, Madrigal-Matute J, Mínguez P, Egido J, Michel J-B et al. A major role of TWEAK/Fn14 axis as a therapeutic target for post-angioplasty restenosis. EBioMedicine. 2019;46:274–89. DOI: 10.1016/j.ebiom.2019.07.072

7. Martínez-Miguel P, Medrano-Andrés D, Griera-Merino M, Ortiz A, Rodríguez-Puyol M, Rodríguez-Puyol D et al. Tweak up-regulates endothelin-1 system in mouse and human endothelial cells. Cardiovascular Research. 2017;113(2):207–21. DOI: 10.1093/cvr/cvw239

8. Moreno JA, Muñoz-García B, Martín-Ventura JL, Madrigal-Matute J, Orbe J, Páramo JA et al. The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. Atherosclerosis. 2009;207(1):103–10. DOI: 10.1016/j.atherosclerosis.2009.04.033

9. Akahori H, Karmali V, Polavarapu R, Lyle AN, Weiss D, Shin E et al. CD163 interacts with TWEAK to regulate tissue regeneration after ischaemic injury. Nature Communications. 2015;6(1):7792. DOI: 10.1038/ncomms8792

10. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD et al. Third universal definition of myocardial infarction. Journal of the American College of Cardiology. 2012;60(16):1581–98. DOI: 10.1016/j.jacc.2012.08.001

11. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal. 2018;39(2):119–77. DOI: 10.1093/eurheartj/ehx393

12. Jarr K-U, Eschricht S, Burkly LC, Preusch M, Katus HA, Frey N et al. TNF-Like Weak Inducer of Apoptosis Aggravates Left Ventricular Dysfunction after Myocardial Infarction in Mice. Mediators of Inflammation. 2014;2014:131950. DOI: 10.1155/2014/131950

13. Bulluck H, Go YY, Crimi G, Ludman AJ, Rosmini S, Abdel-Gadir A et al. Defining left ventricular remodeling following acute ST-segment elevation myocardial infarction using cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance. 2017;19(1):26. DOI: 10.1186/s12968-017-0343-9

14. Ferhat E, Karabekir E, Gultekin K, Orhan K, Onur Y, Nilnur E. Evaluation of the relationship between anti-inflammatory cytokines and adverse cardiac remodeling after myocardial infarction. Kardiologiia. 2021;61(10):61–70. DOI: 10.18087/cardio.2021.10.n1749

15. Unudurthi SD, Nassal DM, Patel NJ, Thomas E, Yu J, Pierson CG et al. Fibroblast growth factor-inducible 14 mediates macrophage infiltration in heart to promote pressure overload-induced cardiac dysfunction. Life Sciences. 2020;247:117440. DOI: 10.1016/j.lfs.2020.117440

16. Das NA, Carpenter AJ, Yoshida T, Kumar SA, Gautam S, Mostany R et al. TRAF3IP2 mediates TWEAK/TWEAKR-induced pro-fibrotic responses in cultured cardiac fibroblasts and the heart. Journal of Molecular and Cellular Cardiology. 2018;121:107–23. DOI: 10.1016/j.yjmcc.2018.07.003

17. Kologrivova IV, Suslova T, Koshelskaya O, Trubacheva O, Haritonova O, Vinnitskaya I. Frequency of monocyte subsets is linked to the severity of atherosclerosis in patients with ischemic heart disease: a case-control study. BioMedicine. 2020;10(2):36–47. DOI: 10.37796/2211-8039.1015

18. Dirajlal-Fargo S, Sattar A, Kulkarni M, Funderburg N, McComsey GA. Soluble TWEAK may predict carotid atherosclerosis in treated HIV infection. HIV Clinical Trials. 2017;18(4):156–63. DOI: 10.1080/15284336.2017.1366001

19. Ptaszynska-Kopczynska K, Marcinkiewicz-Siemion M, Lisowska A, Waszkiewicz E, Witkowski M, Jasiewicz M et al. Alterations of soluble TWEAK and CD163 concentrations in patients with chronic heart failure. Cytokine. 2016;80:7–12. DOI: 10.1016/j.cyto.2016.02.005

20. Chicheportiche Y, Chicheportiche R, Sizing I, Thompson J, Benjamin CB, Ambrose C et al. Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies. Arthritis Research. 2002;4(2):126–33. DOI: 10.1186/ar388

21. Ebihara N, Nakayama M, Tokura T, Ushio H, Murakami A. Expression and function of fibroblast growth factor-inducible 14 in human corneal myofibroblasts. Experimental Eye Research. 2009;89(2):256–62. DOI: 10.1016/j.exer.2009.03.014

22. Ratajczak W, Atkinson SD, Kelly C. The TWEAK/Fn14/CD163 axis-implications for metabolic disease. Reviews in Endocrine and Metabolic Disorders. 2022;23(3):449–62. DOI: 10.1007/s11154-021-09688-4

23. Jain M, Jakubowski A, Cui L, Shi J, Su L, Bauer M et al. A Novel Role for Tumor Necrosis Factor–Like Weak Inducer of Apoptosis (TWEAK) in the Development of Cardiac Dysfunction and Failure. Circulation. 2009;119(15):2058–68. DOI: 10.1161/CIRCULATIONAHA.108.837286